Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2015, Article ID 151269, 6 pages
http://dx.doi.org/10.1155/2015/151269
Case Report

Rare Cause of Wide QRS Tachycardia

1Department of Clinical Electrophysiology, Russian Cardiology Research Center, Russia
2Department of Sonography, Russian Cardiology Research Center, Russia
3Department of Tomography, Russian Cardiology Research Center, Russia

Received 20 August 2015; Accepted 17 November 2015

Academic Editor: Hiroaki Kitaoka

Copyright © 2015 Nikolay Yu. Mironov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. T. Darras and D. A. Chad, “Myotonic dystrophy: etiology, clinical features, and diagnosis,” May 2015, http://www.uptodate.com/contents/myotonic-dystrophy-etiology-clinical-features-and-diagnosis.
  2. J. Mathieu, P. Allard, L. Potvin, C. Prévost, and P. Begin, “A 10-year study of mortality in a cohort of patients with myotonic dystrophy,” Neurology, vol. 52, no. 8, pp. 1658–1662, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. V. A. Sansone, E. Brigonzi, B. Schoser et al., “The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes,” International Journal of Cardiology, vol. 168, no. 2, pp. 1147–1153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. W. J. Groh, M. R. Groh, C. Saha et al., “Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2688–2697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. F. Phillips and P. S. Harper, “Cardiac disease in myotonic dystrophy,” Cardiovascular Research, vol. 33, no. 1, pp. 13–22, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Pelargonio, A. Dello Russo, T. Sanna, G. De Martino, and F. Bellocci, “Myotonic dystrophy and the heart,” Heart, vol. 88, no. 6, pp. 665–670, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Brignole, A. Auricchio, G. Baron-Esquivias et al., “2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapyThe Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA),” Europace, vol. 15, no. 8, pp. 1070–1118, 2013. View at Publisher · View at Google Scholar
  8. B. Udd and R. Krahe, “The myotonic dystrophies: molecular, clinical, and therapeutic challenges,” The Lancet Neurology, vol. 11, no. 10, pp. 891–905, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. L. Merino, J. R. Carmona, I. Fernández-Lozano, R. Peinado, N. Basterra, and J. A. Sobrino, “Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation,” Circulation, vol. 98, no. 6, pp. 541–546, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Bhakta, C. Shen, J. Kron, A. E. Epstein, R. M. Pascuzzi, and W. J. Groh, “Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population,” Journal of Cardiovascular Electrophysiology, vol. 22, no. 12, pp. 1369–1375, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M.-L. Caillet-Boudin, F.-J. Fernandez-Gomez, H. Tran, C.-M. Dhaenens, L. Buee, and N. Sergeant, “Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy,” Frontiers in Molecular Neuroscience, vol. 6, article 57, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Reithmann, B. Herkommer, A. Huemmer, F. Von Hoch, and M. Fiek, “The risk of delayed atrioventricular and intraventricular conduction block following ablation of bundle branch reentry,” Clinical Research in Cardiology, vol. 102, no. 2, pp. 145–153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. G. D. Vladutiu, Z. Simmons, P. J. Isackson et al., “Genetic risk factors associated with lipid-lowering drug-induced myopathies,” Muscle and Nerve, vol. 34, no. 2, pp. 153–162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. B. J. Gersh, B. J. Maron, R. O. Bonow et al., “2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy,” Circulation, vol. 124, no. 24, pp. e783–e831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Olivotto, F. Cecchi, S. A. Casey, A. Dolara, J. H. Traverse, and B. J. Maron, “Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy,” Circulation, vol. 104, no. 21, pp. 2517–2524, 2001. View at Publisher · View at Google Scholar · View at Scopus